Select your localized edition:

Close ×

More Ways to Connect

Discover one of our 28 local entrepreneurial communities »

Be the first to know as we launch in new countries and markets around the globe.

Interested in bringing MIT Technology Review to your local market?

MIT Technology ReviewMIT Technology Review - logo


Unsupported browser: Your browser does not meet modern web standards. See how it scores »

{ action.text }

Migraine sufferers may soon be able to shock their pain away. New research suggests that transcranial magnetic stimulation, a non-invasive technique to stimulate parts of the brain, can provide pain relief to migraine sufferers, if delivered soon after the onset of symptoms. And researchers are now testing a portable version of such a stimulator.

In transcranial magnetic stimulation, or TMS, an electromagnet is held against a patient’s head, emitting a magnetic field that creates an electrical current in the brain. Originally developed about two decades ago, new incarnations of the TMS technique are also being tested as a treatment for depression and other disorders.

Currently, drugs called triptans are the most common treatment for migraines. They target specific receptors in the brain, stopping pain and other migraine symptoms. Although triptans help many people, they’re ineffective in about one-third of cases, or approximately nine million Americans. “There’s a need for alternatives,” says Yousef Mohammad, M.D. and associate professor of neurology at Ohio State University, who ran the new trials.

At a meeting of the American Headache Society in Los Angeles this week, Mohammad presented data from two pilot studies testing TMS for migraine. In the first study, 42 patients reported to the hospital on first signs of migraine. About half were treated with a stationary device that delivered two pulses of magnetic energy, each lasting less than a millisecond, at about the strength of an MRI. The other half received placebo treatments, in which no pulses were delivered.

According to the findings, in the TMS group, patients reported that about 70 percent of their headaches were mild or no longer painful within two hours, compared with 48 percent in the placebo group. The TMS group also reported relief from other migraine symptoms, including nausea and sensitivity to light and noise, and no side effects. Mohammad says the results were encouraging, but cautions that, given the small number of patients in the study, it’s difficult to determine whether the numbers are statistically significant.

Mohammad’s team also tested a portable TMS device made by Neuralieve, a medical technology company in Sunnyvale, CA. Meant for home use, it allows patients to treat themselves by holding the device (which resembles a hairdryer) against their heads, and pressing a button that delivers the magnetic energy in two pulses with the same strength and duration as the nonportable version. In an uncontrolled study of 12 patients, the device was able to relieve or reduce 80 percent of patients’ headaches.

5 comments. Share your thoughts »

Tagged: Biomedicine

Reprints and Permissions | Send feedback to the editor

From the Archives


Introducing MIT Technology Review Insider.

Already a Magazine subscriber?

You're automatically an Insider. It's easy to activate or upgrade your account.

Activate Your Account

Become an Insider

It's the new way to subscribe. Get even more of the tech news, research, and discoveries you crave.

Sign Up

Learn More

Find out why MIT Technology Review Insider is for you and explore your options.

Show Me